| 1 |
34449248 | A New Old Target: Androgen Receptor Signaling and Advanced Prostate Cancer. | 2022 Jan 6 |
3 |
| 2 |
34648657 | A European, prospective, observational study of enzalutamide in patients with metastatic castration-resistant prostate cancer: PREMISE. | 2022 Mar 1 |
1 |
| 3 |
34728570 | Targeting DNMTs to Overcome Enzalutamide Resistance in Prostate Cancer. | 2022 Jan |
2 |
| 4 |
34740892 | Loss of Long Noncoding RNA NXTAR in Prostate Cancer Augments Androgen Receptor Expression and Enzalutamide Resistance. | 2022 Jan 1 |
3 |
| 5 |
34763937 | Phase II study of enzalutamide in androgen receptor positive, recurrent, high- and low-grade serous ovarian cancer. | 2022 Jan |
2 |
| 6 |
34807458 | Phase I clinical trial of HC-1119 soft capsule in Chinese healthy adult male subjects: Pharmacokinetics and safety of single-dose proportionality and effects of food. | 2022 Feb |
3 |
| 7 |
34937944 | Targeting SWI/SNF ATPases in enhancer-addicted prostate cancer. | 2022 Jan |
1 |
| 8 |
35058329 | (+)-JJ-74-138 is a Novel Noncompetitive Androgen Receptor Antagonist. | 2022 Apr 1 |
3 |
| 9 |
35229000 | Prognostic significance of risk stratification in CHAARTED and LATITUDE studies among Japanese men with castration-resistant prostate cancer. | 2022 Mar |
1 |
| 10 |
35271265 | Application of Surface-Enhanced Raman Spectroscopy to Guide Therapy for Advanced Prostate Cancer Patients. | 2022 Mar 25 |
3 |
| 11 |
35337811 | Chemical degrader enhances the treatment of androgen receptor-positive triple-negative breast cancer. | 2022 May 30 |
1 |
| 12 |
35352309 | Real-World Effectiveness of Sipuleucel-T on Overall Survival in Men with Advanced Prostate Cancer Treated with Androgen Receptor-Targeting Agents. | 2022 Jun |
1 |
| 13 |
35363301 | Phase Ib/II Study of Enzalutamide with Samotolisib (LY3023414) or Placebo in Patients with Metastatic Castration-Resistant Prostate Cancer. | 2022 Jun 1 |
1 |
| 14 |
35372002 | Prognostic and Predictive Value of Liquid Biopsy-Derived Androgen Receptor Variant 7 (AR-V7) in Prostate Cancer: A Systematic Review and Meta-Analysis. | 2022 |
1 |
| 15 |
35372068 | Anti-Androgen Receptor Therapies in Prostate Cancer: A Brief Update and Perspective. | 2022 |
1 |
| 16 |
35385726 | Mesenchymal and stem-like prostate cancer linked to therapy-induced lineage plasticity and metastasis. | 2022 Apr 5 |
2 |
| 17 |
35390118 | Targeting the androgen receptor signaling pathway in advanced prostate cancer. | 2022 Apr 7 |
2 |
| 18 |
35428760 | RNF8 up-regulates AR/ARV7 action to contribute to advanced prostate cancer progression. | 2022 Apr 15 |
1 |
| 19 |
35452181 | Both SUMOylation and ubiquitination of TFE3 fusion protein regulated by androgen receptor are the potential target in the therapy of Xp11.2 translocation renal cell carcinoma. | 2022 Apr |
2 |
| 20 |
35504877 | Non-drug efflux function of ABCC5 promotes enzalutamide resistance in castration-resistant prostate cancer via upregulation of P65/AR-V7. | 2022 May 3 |
1 |
| 21 |
35510101 | Prognostic impact of dose reduction in androgen receptor pathway inhibitors for castration-resistant prostate cancer. | 2022 Mar |
1 |
| 22 |
35513478 | Grade group system and plasma androgen receptor status in the first line treatment for metastatic castration resistant prostate cancer. | 2022 May 5 |
4 |
| 23 |
35523048 | Antagonistic action of a synthetic androgen ligand mediated by chromatin remodeling in a human prostate cancer cell line. | 2022 Jul 5 |
6 |
| 24 |
35533600 | Lycopene enhances the sensitivity of castration-resistant prostate cancer to enzalutamide through the AKT/EZH2/ androgen receptor signaling pathway. | 2022 Jul 12 |
2 |
| 25 |
35534851 | Natural product myricetin is a pan-KDM4 inhibitor which with poly lactic-co-glycolic acid formulation effectively targets castration-resistant prostate cancer. | 2022 May 9 |
1 |
| 26 |
35553247 | Decisions and dilemmas in non-metastatic castration-resistant prostate cancer management. | 2022 May 13 |
1 |
| 27 |
35565349 | Baseline Plasma Tumor DNA (ctDNA) Correlates with PSA Kinetics in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Abiraterone or Enzalutamide. | 2022 Apr 29 |
1 |
| 28 |
35579577 | Factors that guide selection among androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer. | 2022 May |
1 |
| 29 |
35590370 | The DNA/RNA helicase DHX9 contributes to the transcriptional program of the androgen receptor in prostate cancer. | 2022 May 19 |
1 |
| 30 |
31558422 | Progression-directed Therapy for Oligoprogression in Castration-refractory Prostate Cancer. | 2021 Apr |
1 |
| 31 |
31676281 | Improved Androgen Receptor Splice Variant 7 Detection Using a Highly Sensitive Assay to Predict Resistance to Abiraterone or Enzalutamide in Metastatic Prostate Cancer Patients. | 2021 Aug |
2 |
| 32 |
32624280 | A Multicohort Open-label Phase II Trial of Bipolar Androgen Therapy in Men with Metastatic Castration-resistant Prostate Cancer (RESTORE): A Comparison of Post-abiraterone Versus Post-enzalutamide Cohorts. | 2021 May |
1 |
| 33 |
32881669 | Darolutamide as a Second-Generation Androgen Receptor Inhibitor in the Treatment of Prostate Cancer. | 2021 |
1 |
| 34 |
32954481 | Isolation and characterization of castration-resistant prostate cancer LNCaP95 clones. | 2021 Jan |
3 |
| 35 |
32958445 | Androgen receptor inhibitor treatments: Cardiovascular adverse events and comorbidity considerations in patients with non-metastatic prostate cancer. | 2021 Jan |
1 |
| 36 |
33140306 | Endocrine consequences of treatment with the new androgen receptor axis-targeted agents for advanced prostate cancer. | 2021 Mar |
1 |
| 37 |
33150960 | Mechanisms of enzalutamide resistance in castration-resistant prostate cancer and therapeutic strategies to overcome it. | 2021 Jan |
3 |
| 38 |
33271252 | Functional characterization of androgen receptor in two patient-derived xenograft models of triple negative breast cancer. | 2021 Feb |
1 |
| 39 |
33277366 | KIF15-Mediated Stabilization of AR and AR-V7 Contributes to Enzalutamide Resistance in Prostate Cancer. | 2021 Feb 15 |
4 |
| 40 |
33277796 | A review of the effects and molecular mechanisms of dimethylcurcumin (ASC-J9) on androgen receptor-related diseases. | 2021 Apr |
1 |
| 41 |
33388655 | Design, synthesis and biological evaluation of novel thiohydantoin derivatives as potent androgen receptor antagonists for the treatment of prostate cancer. | 2021 Feb 1 |
3 |
| 42 |
33432555 | Clinicopathological Features and Treatment Challenges in Triple Negative Breast Cancer Patients: A Retrospective Cohort Study. | 2021 |
2 |
| 43 |
33436326 | Circulating Androgen Receptor for Prognosis and Treatment Selection in Prostate Cancer. | 2021 Oct |
3 |
| 44 |
33441906 | Regulation of carcinogenesis and mediation through Wnt/β-catenin signaling by 3,3'-diindolylmethane in an enzalutamide-resistant prostate cancer cell line. | 2021 Jan 13 |
4 |
| 45 |
33470111 | Discovery of JNJ-63576253: A Clinical Stage Androgen Receptor Antagonist for F877L Mutant and Wild-Type Castration-Resistant Prostate Cancer (mCRPC). | 2021 Jan 28 |
2 |
| 46 |
33500577 | Androgen receptor gain in circulating free DNA and splicing variant 7 in exosomes predict clinical outcome in CRPC patients treated with abiraterone and enzalutamide. | 2021 Jun |
1 |
| 47 |
33517325 | Synthesis and Evaluation of 18F-Enzalutamide, a New Radioligand for PET Imaging of Androgen Receptors: A Comparison with 16β-18F-Fluoro-5α-Dihydrotestosterone. | 2021 Aug 1 |
3 |
| 48 |
33562646 | Metformin and Androgen Receptor-Axis-Targeted (ARAT) Agents Induce Two PARP-1-Dependent Cell Death Pathways in Androgen-Sensitive Human Prostate Cancer Cells. | 2021 Feb 5 |
1 |
| 49 |
33563753 | V-ATPase Inhibition Decreases Mutant Androgen Receptor Activity in Castrate-resistant Prostate Cancer. | 2021 Apr |
3 |
| 50 |
33574348 | Inhibition of androgen/AR signaling inhibits diethylnitrosamine (DEN) induced tumour initiation and remodels liver immune cell networks. | 2021 Feb 11 |
1 |